CORCEPT THERAPUETICS RECRUITING STUDIES:

• CORT125134-456 (GRADIENT) – Hypercortisolism

The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The study duration is around 30 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• CORT125134-452 – Open-Label Extension Trial For Cushing Syndrome

An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

CORCEPT THERAPUETICS NON-RECRUITING STUDIES:

• CORT125134-455 (GRACE) – Cushing Syndrome

COMPLETED STUDIES:

  • AbbVie – M16-100 (TRAVERSE) – Hypogonadism/CVD – 2023

  • Acasti Pharma – ACA-CAP-002 (TRILOGY2) – Hypertriglyceridemia – 2020

  • Cortendo AB – COR-2012-01 – Cushing Syndrome – 2018

  • Teva Branded Pharmaceutical Products R&D, Inc. – TV1106-IMM-30021 – Growth Hormone Deficiency – 2015

  • Teva Branded Pharmaceutical Products R&D, Inc. – TV1106-IMM-30022 – Growth Hormone Deficiency – 2016

info@PlanItResearch.com